Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, Won | - |
dc.contributor.author | Cho, Ju-Yeon | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.contributor.author | Woo, Min-Ah | - |
dc.contributor.author | Jung, Sin-Ho | - |
dc.contributor.author | Paik, Yong-Han | - |
dc.date.accessioned | 2021-09-03T05:42:16Z | - |
dc.date.available | 2021-09-03T05:42:16Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83336 | - |
dc.description.abstract | Background/Aims: This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B (CHB). Methods: We investigated 2,061 Korean treatment-naive patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated. Results: The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15xgender [female=0/male=1]+23xcirrhosis [absence=0/presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001). Conclusions: The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naive CHB patients receiving entecavir. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC STUDY LIVER | - |
dc.subject | PRACTICE GUIDELINES MANAGEMENT | - |
dc.subject | ENTECAVIR TREATMENT | - |
dc.subject | PREDICTIVE SCORE | - |
dc.subject | VIRUS INFECTION | - |
dc.subject | THERAPY | - |
dc.subject | VALIDATION | - |
dc.subject | CIRRHOSIS | - |
dc.title | Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.identifier.doi | 10.3350/cmh.2016.0086 | - |
dc.identifier.wosid | 000407836000011 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, v.23, no.2, pp.170 - 178 | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.title | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.volume | 23 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 170 | - |
dc.citation.endPage | 178 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002231733 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PRACTICE GUIDELINES MANAGEMENT | - |
dc.subject.keywordPlus | ENTECAVIR TREATMENT | - |
dc.subject.keywordPlus | PREDICTIVE SCORE | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Assessment, Risk | - |
dc.subject.keywordAuthor | Antiviral drugs | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.